Glomerular hyperfiltration: Definitions, mechanisms and clinical implications

Nature Reviews Nephrology

Volumn 8, Issue 5, 2012, Pages 293-300

  Helal, Imed ^a   Fick Brosnahan, Godela M ^a   Reed Gitomer, Berenice ^a   Schrier, Robert W ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOHIPPURIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; RELAXIN;

ALTITUDE DISEASE; BLOOD DISEASE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CREATININE CLEARANCE; CRUSH SYNDROME; DIABETES MELLITUS; ENZYME ACTIVITY; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; KIDNEY BLOOD FLOW; KIDNEY PLASMA FLOW; KIDNEY POLYCYSTIC DISEASE; KIDNEY TUMOR; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PODOCYTE; PREGNANCY; PRIORITY JOURNAL; PROTEIN DIET; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW; SICKLE CELL ANEMIA; SLEEP APNEA SYNDROME;

ANIMALS; DIABETES MELLITUS; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HEMODYNAMICS; HUMANS; KIDNEY GLOMERULUS; NEPHRONS; OBESITY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PREGNANCY; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; SLEEP APNEA SYNDROMES; VASODILATION;

EID: 84860279587     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2012.19     Document Type: Review

References (98)

1. Bergström, J., Ahlberg, M. & Alvestrand, A. Influence of protein intake on renal hemodynamics and plasma hormone concentrations in normal subjects. Acta Med. Scand. 217, 189-196 (1985). (Pubitemid 15144055)
2. Pecly, I. M., Genelhu, V. & Francischetti, E. A. Renal functional reserve in obesity hypertension. Int. J. Clin. Pract. 60, 1198-1203 (2006). (Pubitemid 44375440)
3. Bosch, J. P., Lauer, A. & Glabman, S. Short-term protein loading in assessment of patients with renal disease. Am. J. Med. 77, 873-879 (1984). (Pubitemid 15204867)
4. Brenner, B. M., Hostetter, T. H., Olson, J. L., Rennke, H. G. & Venkatachalam, M. A. The role of glomerular hyperfiltration in the initiation and progression of diabetic nephropathy. Acta Endocrinol. Suppl. (Copenh.) 242, 7-10 (1981). (Pubitemid 11037025)
5. Brenner, B. M., Lawler, E. V. & Mackenzie, H. S. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int. 49, 1774-1777 (1996). (Pubitemid 26186610)
6. Hostetter, T. H., Olson, J. L., Rennke, H. G., Venkatachalam, M. A. & Brenner, B. M. Hyperfiltration in remnant nephrons: a potentially adverse response to rena ablation. Am. J. Physiol. 241, F85-F93 (1981). (Pubitemid 11033923)
7. Hostetter, T. H., Troy, J. L. & Brenner, B. M. Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int. 19, 410-415 (1981). (Pubitemid 11112621)
8. Brenner, B. M. Nephron adaptation to renal njury or ablation. Am. J. Physiol. 249, F324-F337 (1985). (Pubitemid 16225762)
9. Anderson, S. & Brenner, B. M. The role of ntraglomerular pressure in the initiation and progression of renal disease. J. Hypertens. Suppl. 4, S236-S238 (1986). (Pubitemid 17054511)
10. Neuringer, J. R. & Brenner, B. M. Glomerular hypertension: cause and consequence of renal njury. J. Hypertens. Suppl. 10, S91-S97 (1992). (Pubitemid 23045176)
11. Neuringer, J. R. & Brenner, B. M. Hemodynamic theory of progressive renal disease: a 10-year update in brief review. Am. J. Kidney Dis. 22, 98-104 (1993). (Pubitemid 23203506)
12. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Part 4. Definition and classification of stages of chronic kidney disease. Am. J. Kidney Dis. 39, S46-S75 (2002).
13. Dahlquist, G., Stattin, E. L. & Rudberg, S. Urinary albumin excretion rate and glomerular filtration rate in the prediction of diabetic nephropathy; a long-term follow-up study of childhood onset type-1 diabetic patients. Nephrol. Dial. Transplant 16, 1382-1386 (2001). (Pubitemid 32640592)
14. Amin, R. et al. The relationship between microalbuminuria and glomerular filtration rate in young type 1 diabetic subjects: The Oxford Regional Prospective Study. Kidney Int. 68, 1740-1749 (2005). (Pubitemid 43169918)
15. Chaiken, R. L. et al. Hyperfiltration in African-American patients with type 2 diabetes. Cross-sectional and longitudinal data. Diabetes Care 21, 2129-2134 (1998). (Pubitemid 28549162)
16. Hjorth, L., Wiebe, T. & Karpman, D. Hyperfiltration evaluated by glomerular filtration rate at diagnosis in children with cancer. Pediatr. Blood Cancer 56, 762-766 (2011).
17. Huang, S. H. et al. Hyperfiltration affects accuracy of creatinine eGFR measurement. Clin. J. Am. Soc. Nephrol. 6, 274-280 (2011).
18. Stevens, L. A., Coresh, J., Greene, T. & Levey, A. S. Assessing kidney function\measured and estimated glomerular filtration rate. N. Engl. J. Med. 354, 2473-2483 (2006). (Pubitemid 43855050)
19. Cadnapaphornchai, M., Briner, V. & Schrier, R. W. in Renal and Electrolyte Disorders (ed. Schrier, R. W.) 539-579 (Lippincott Williams & Wilkins, Philadelphia, 2003).
20. Schrier, R. W. & Ohara, M. Dilemmas in human and rat pregnancy: proposed mechanisms relating to arterial vasodilation. J. Neuroendocrinol. 22, 400-406 (2010).
21. Schrier, R. W. Systemic arterial vasodilation, vasopressin, and vasopressinase in pregnancy. J. Am. Soc. Nephrol. 21, 570-572 (2010).
22. Chapman, A. B. et al. Temporal relationships between hormonal and hemodynamic changes in early human pregnancy. Kidney Int 54, 2056-2063 (1998). (Pubitemid 28533634)
23. Conrad, K. P., Jeyabalan, A., Danielson, L. A., Kerchner, L. J. & Novak, J. Role of relaxin in maternal renal vasodilation of pregnancy. Ann. NY Acad. Sci. 1041, 147-154 (2005). (Pubitemid 41132240)
24. Conrad, K. P. Mechanisms of renal vasodilation and hyperfiltration during pregnancy. J. Soc. Gynecol. Investig. 11, 438-448 (2004). (Pubitemid 39349195)
25. Cadnapaphornchai, M. A. et al. Chronic NOS inhibition reverses systemic vasodilation and glomerular hyperfiltration in pregnancy. Am. J. Physiol. Renal Physiol. 280, F592-F598 (2001).
26. Gumus, I. I. et al. Does glomerular hyperfiltration in pregnancy damage the kidney in women with more parities? Int. Urol. Nephrol. 41, 927-932 (2009).
27. Bank, N. Mechanisms of diabetic hyperfiltration. Kidney Int 40, 792-807 (1991).
28. Levine, D. Z. Can rodent models of diabetic kidney disease clarify the significance of early hyperfiltration?: recognizing clinical and experimental uncertainties. Clin. Sci. (Lond.) 114, 109-118 (2008).
29. Vora, J. P. et al. Renal hemodynamics in newly presenting non-insulin dependent diabetes mellitus. Kidney Int 41, 829-835 (1992).
30. Nelson, R. G. et al. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N. Engl. J. Med. 335, 1636-1642 (1996). (Pubitemid 26392728)
31. Keller, C. K., Bergis, K. H., Fliser, D. & Ritz, E. Renal findings in patients with short-term type 2 diabetes. J. Am. Soc. Nephrol. 7, 2627-2635 (1996). (Pubitemid 27469569)
32. O'Bryan, G. T. & Hostetter, T. H. The renal hemodynamic basis of diabetic nephropathy Semin. Nephrol. 17, 93-100 (1997). (Pubitemid 27124034)
33. Zatz, R., Meyer, T. W., Rennke, H. G. & Brenner, B. M. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc. Natl Acad. Sci. USA 82, 5963-5967 (1985). (Pubitemid 16218883)
34. Hirschberg, R., Brunori, G., Kopple, J. D. & Guler, H. P. Effects of insulin-like growth factor on renal function in normal men. Kidney Int 43, 387-397 (1993). (Pubitemid 23162832)
35. Anderson, S. & Vora, J. P. Current concepts of renal hemodynamics in diabetes. J. Diabetes Complications 9, 304-307 (1995).
36. Sabbatini, M. et al. Early glycosylation products induce glomerular hyperfiltration in normal rats. Kidney Int 42, 875-881 (1992).
37. Veelken, R. et al. Nitric oxide synthase isoforms and glomerular hyperfiltration in early diabetic nephropathy. J. Am. Soc. Nephrol. 11, 71-79 (2000). (Pubitemid 30020428)
38. Kuno, Y., Iyoda, M., Shibata, T, Hirai, Y. & Akizawa, T. Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima Fatty rats. Br. J. Pharmacol. 162, 1389-1400 (2011).
39. Magee, G. M. et al. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 52, 691-697 (2009).
40. Vallon, V., Richter, K., Blantz, R. C., Thomson, S. & Osswald, H. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J. Am. Soc. Nephrol. 10, 2569-2576 (1999).
41. Thomson, S. C. et al. Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes. J. Clin. Invest. 107, 217-224 (2001). (Pubitemid 32096838)
42. Vervoort, G., Veldman, B., Berden, J. H., Smits, P. & Wetzels, J. F. Glomerular hyperfiltration in type 1 diabetes mellitus results from primary changes in proximal tubular sodium handling without changes in volume expansion. Eur. J. Clin. Invest. 35, 330-336 (2005). (Pubitemid 40691281)
43. Pruijm, M. et al. Glomerular hyperfiltration and increased proximal sodium reabsorption in subjects with type 2 diabetes or impaired fasting glucose in a population of the African region. Nephrol. Dial. Transplant. 25, 2225-2231 (2010).
44. Sällström, J. et al. Diabetes-induced hyperfiltration in adenosine A1-receptor deficient mice lacking the tubuloglomerular feedback mechanism. Acta Physiol. (Oxf.) 190, 253-259 (2007). (Pubitemid 46934662)
45. Venezia, A. et al. Dietary sodium intake in a sample of adult male population in southern Italy: results of the Olivetti Heart Study. Eur. J. Clin. Nutr. 64, 518-524 (2010).
46. Chagnac, A. et al. Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption. Nephrol. Dial. Transplant. 23, 3946-3952 (2008).
47. Ficociello, L. H. et al. Renal hyperfiltration and the development of microalbuminuria in type 1 diabetes. Diabetes Care 32, 889-893 (2009).
48. th edn (ed. Schrier, R. W.) 502-539 (Lippincott Williams & Wilkins, Philadelphia, 2007).
49. Franz, K. A. & Reubi, F. C. Rate of functional deterioration in polycystic kidney disease. Kidney Int. 23, 526-529 (1983). (Pubitemid 13117121)
50. Fick-Brosnahan, G. M., Belz, M. M., McFann, K. K., Johnson, A. M. & Schrier, R. W. Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study. Am. J. Kidney Dis. 39, 1127-1134 (2002). (Pubitemid 34591926)
51. Grantham, J. J., Chapman, A. B. & Torres, V. E. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin. J. Am. Soc. Nephrol. 1, 148-157 (2006).
52. Meijer, E. et al. Early renal abnormalities in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 5, 1091-1098 (2010).
53. Torres, V. E. et al. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 2, 112-120 (2007).
54. Dimitrakov, D., Kumchev, E., Lyutakova, E. & Grigorov, L. Glomerular hyperfiltration and serum beta 2-microglobulin used as early markers in diagnosis of autosomal dominant polycystic kidney disease. Folia Med. (Plovdiv) 35, 59-62 (1993).
55. Wong, H., Vivian, L., Weiler, G. & Filler, G. Patients with autosomal dominant polycystic kidney disease hyperfiltrate early in their disease. Am. J. Kidney Dis. 43, 624-628 (2004). (Pubitemid 38401877)
56. Helal, I. et al. Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 6, 2439-2443 (2011).
57. Volpe, M. et al. The renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease. J. Am. Soc. Nephrol. 13 (Suppl. 3), S173-S178 (2002). (Pubitemid 35216020)
58. Chapman, A. B., Johnson, A., Gabow, P. A. & Schrier, R. W. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N. Engl. J. Med. 323, 1091-1096 (1990). (Pubitemid 20370729)
59. Loghman-Adham, M., Soto, C. E., Inagami, T. & Cassis, S. The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease. Am. J. Physiol. Renal Physiol. 287, F775-F788 (2004). (Pubitemid 39280514)
60. Schrier, R. W. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 20, 1888-1893 (2009).
61. Santin, S. et al. Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome. Clin. J. Am. Soc. Nephrol. 6, 1139-1148 (2011).
62. Ingelfinger, J. R. MYO1E, focal segmental glomerulosclerosis, and the cytoskeleton. N. Engl. J. Med. 365, 368-369 (2011).
63. Rennke, H. G. & Klein, P. S. Pathogenesis and significance of nonprimary focal and segmental glomerulosclerosis. Am. J. Kidney Dis. 13, 443-456 (1989). (Pubitemid 19160779)
64. Praga, M. et al. Absence of hypoalbuminemia despite massive proteinuria in focal segmental glomerulosclerosis secondary to hyperfiltration. Am. J. Kidney Dis. 33, 52-58 (1999). (Pubitemid 29031208)
65. Darouich, S. et al. Clinicopathological characteristics of obesity-associated focal segmental glomerulosclerosis. Ultrastruct. Pathol. 35, 176-182 (2011).
66. Kambham, N., Markowitz, G. S., Valeri, A. M., Lin, J. & D'Agati, V. D. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 59, 1498-1509 (2001). (Pubitemid 32281241)
67. Chen, H. M. et al. Podocyte lesions in patients with obesity-related glomerulopathy. Am. J. Kidney Dis. 48, 772-779 (2006).
68. Praga, M. et al. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int. 58, 2111-2118 (2000).
69. González, E. et al. Factors influencing the progression of renal damage in patients with unilateral renal agenesis and remnant kidney. Kidney Int. 68, 263-270 (2005). (Pubitemid 43181384)
70. Quinn, C. T. et al. for the Thalassemia Clinical Research Network. Renal dysfunction in patients with thalassaemia. Br. J. Haematol. 153, 111-117 (2011).
71. Schmitt, F. et al. Early glomerular dysfunction in patients with sickle cell anemia. Am. J. Kidney Dis. 32, 208-214 (1998).
72. Haymann, J. P. et al. Glomerular hyperfiltration in adult sickle cell anemia: a frequent hemolysis associated feature. Clin. J. Am. Soc. Nephrol. 5, 756-761 (2010).
73. Arestegui, A. H. et al. High altitude renal syndrome (HARS). J. Am. Soc. Nephrol. 22, 1963-1968 (2011).
74. Inatomi, J., Matsuoka, K., Fujimaru, R., Nakagawa, A. & Iijima, K. Mechanisms of development and progression of cyanotic nephropathy. Pediatr. Nephrol. 21, 1440-1445 (2006). (Pubitemid 44283477)
75. Henegar, J. R., Bigler, S. A., Henegar, L. K., Tyagi, S. C. & Hall, J. E. Functional and structural changes in the kidney in the early stages of obesity. J. Am. Soc. Nephrol. 12, 1211-1217 (2001). (Pubitemid 32472634)
76. Ribstein, J., du Cailar, G. & Mimran, A. Combined renal effects of overweight and hypertension. Hypertension 26, 610-615 (1995).
77. Wuerzner, G. et al. Marked association between obesity and glomerular hyperfiltration: a cross-sectional study in an African population. Am. J. Kidney Dis. 56, 303-312 (2010).
78. Levey, A. S. & Kramer, H. Obesity, glomerular hyperfiltration, and the surface area correction. Am. J. Kidney Dis. 56, 255-258 (2010).
79. Goumenos, D. S. et al. Early histological changes in the kidney of people with morbid obesity Nephrol. Dial. Transplant. 24, 3732-3738 (2009).
80. Bosma, R. J., van der Heide, J. J., Oosterop, E. J., de Jong, P. E. & Navis, G. Body mass index is associated with altered renal hemodynamics in non-obese healthy subjects. Kidney Int. 65, 259-265 (2004). (Pubitemid 38037512)
81. Tomaszewski, M. et al. Glomerular hyperfiltration: a new marker of metabolic risk. Kidney Int. 71, 816-821 (2007). (Pubitemid 46624026)
82. Serpa Neto, A. et al. Effect of weight loss after Roux-en-Y gastric bypass, on renal function and blood pressure in morbidly obese patients. J. Nephrol. 22, 637-646 (2009).
83. Navarro-Díaz, M. et al. Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up. J. Am. Soc. Nephrol. 17, S213-S217 (2006). (Pubitemid 44865251)
84. Kinebuchi, S. et al. Short-term use of continuous positive airway pressure ameliorates glomerular hyperfiltration in patients with obstructive sleep apnea syndrome. Clin. Sci. (Lond.) 107, 317-322 (2004). (Pubitemid 39243892)
85. Jennette, J. C., Charles, L. & Grubb, W. Glomerulomegaly and focal segmental glomerulosclerosis associated with obesity and sleep-apnea syndrome. Am. J. Kidney Dis. 10, 470-472 (1987). (Pubitemid 18007347)
86. Casserly, L. F et al. Proteinuria in obstructive sleep apnea. Kidney Int. 60, 1484-1489 (2001). (Pubitemid 32960043)
87. Taal, M. W. & Brenner, B. M. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int. 57, 1803-1817 (2000). (Pubitemid 30252273)
88. Cherney, D. Z. et al. Effect of direct renin inhibition on renal hemodynamic function, arterial stiffness, and endothelial function in humans with uncomplicated type 1 diabetes: a pilot study. Diabetes Care 33, 361-365 (2010).
89. van der Meer, I. M., Cravedi, P. & Remuzzi, G. The role of renin angiotensin system inhibition in kidney repair. Fibrogenesis Tissue Repair 3, 7 (2010).
90. Lewis, E. J., Hunsicker, L. G., Bain, R. P. & Rohde, R. D. for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 329, 1456-1462 (1993). (Pubitemid 23335891)
91. Bakris, G. L. Angiotensin-converting enzyme inhibitors and progression of diabetic nephropathy. Ann. Intern. Med. 118, 643-644 (1993). (Pubitemid 23102701)
92. Brenner, B. M. et al. for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869 (2001).
93. Nobakht, N., Kamgar, M., Rastogi, A. & Schrier, R. W. Limitations of angiotensin nhibition. Nat Rev. Nephrol. 7, 356-359 (2011).
94. Nordquist, L., Lai, E. Y., Sjöquist, M., Patzak, A. & Persson, A. E. Proinsulin C-peptide constricts glomerular afferent arterioles in diabetic mice. A potential renoprotective mechanism. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294, R836-R841 (2008).
95. Pistrosch, F et al. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 54, 2206-2211 (2005). (Pubitemid 40911285)
96. Luippold, G., Beilharz, M. & Mühlbauer, B. Chronic renal denervation prevents glomerular hyperfiltration in diabetic rats. Nephrol. Dial. Transplant. 19, 342-347 (2004). (Pubitemid 38195982)
97. De Paula, R. B., Da Silva, A. A. & Hall, J. E. Aldosterone antagonism attenuates obesity-nduced hypertension and glomerular hyperfiltration. Hypertension 43, 41-47 (2004). (Pubitemid 38031909)
98. Ix, J. H. & Sharma, K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J. Am. Soc. Nephrol. 21, 406-412 (2010).